Rachel Salzman DVM

Dr. Rachel Salzman serves as the Executive Vice President of Portfolio, External Affairs & Development at Alcyone Therapeutics. Rachel co-founded SwanBio Therapeutics in 2017 and served as Chief Executive Officer (CEO) and Director through 2019. She was the company's President and Chief Portfolio & Development Officer until January 2021. She then founded UltraSquared Bio, a not-for-profit organization dedicated to bringing gene therapies to ultra-rare populations where traditional business cases are not tractable.

Prior to her time at Swan, she was the Chief Science Officer (CSO) of The Stop ALD Foundation since 2001. For over 15 years Dr. Salzman has provided drug development expertise and advice to biopharmaceutical industry executives working in the rare disease space where complex biological and business issues intersect with serious unmet medical needs.

Dr. Salzman has been an active member of ASGCT (American Society of Gene and Cell Therapy) for over 15 years and has served in a leadership capacity including multiple committees and task forces designed to build and enhance the state of gene and cell therapy in both the US and EU. Her many contributions were formally recognized by being designated the Sonia Skarlatos Public Service Award recipient in 2015. She currently serves as an elected member of the Executive Board of Directors and as the former inaugural Chair of the Government Relations Committee, which includes representing ASGCT at the National Academy of Sciences.